So lately I’ve been seeing posts on ST that suggest that AVXL , if approved will have a sell the news event and that share price will not be significant until much later (with revenue ). AVXL share price has in the past not seen the value that other CNS companies have had - even if it was brief (see SAVA). To the longs on this board , what are your expectations? I’ve been in biotech for 10 years now. I have seen this unfortunately. Companies with approved drugs that just never turn the corner. I recognize that ALZ, Parkinson’s and other CNS diseases are a different animal when it comes to drug companies with approved drugs. Just wanted to get informed thoughts on this while being fully aware that no one can predict how it will go with what I hope is approval of Blarcamesine. Thx in advance.
Market Data 
Markets 
AI
